<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023096</url>
  </required_header>
  <id_info>
    <org_study_id>HM20022060</org_study_id>
    <secondary_id>1R01DA050996-01A1</secondary_id>
    <nct_id>NCT05023096</nct_id>
  </id_info>
  <brief_title>Potential Effects of Electronic Nicotine Delivery System Flavor Regulations on African American Menthol Smokers</brief_title>
  <acronym>RVA Flavors</acronym>
  <official_title>Effects of Electronic Nicotine Delivery System Flavor Regulations on Tobacco Behavior, Toxicity, and Abuse Liability Among African American Menthol Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to better understand how the availability of electronic nicotine delivery&#xD;
      system (aka electronic cigarettes) flavors (e.g., menthol, tobacco) impacts tobacco use&#xD;
      behaviors, toxicant exposure, and abuse liability among African American menthol smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Black/African American (AA) menthol smokers are disproportionately harmed by tobacco products&#xD;
      and could experience significant health benefits from increased availability of&#xD;
      well-regulated electronic nicotine delivery systems (ENDS). The current study will evaluate&#xD;
      whether ENDS flavor availability affects measures of tobacco use, biomarkers of&#xD;
      cigarette/ENDS exposure, and addiction among AA menthol smokers by performing a 3-arm, 6-week&#xD;
      clinical trial of ENDS provision with follow-up to 30 days. Results of this work will help&#xD;
      FDA make predictions about the impact of moving from the current regulatory market were&#xD;
      menthol/tobacco flavored ENDS cartridges are available, to one where only tobacco or&#xD;
      unflavored cartridges are available, in order to maximize health-promoting effects and&#xD;
      minimize unintended consequences among AA menthol smokers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Average Daily Cigarette Use</measure>
    <time_frame>Week 1 vs. Week 6</time_frame>
    <description>Number of cigarettes used in the past day, collected via daily text survey, averaged over the past week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Carbon Monoxide Exposure</measure>
    <time_frame>Week 1 vs. Week 6</time_frame>
    <description>A biomarker of combusted cigarette use collected from exhaled breath</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Willingness to Substitute from Cigarettes to ENDS</measure>
    <time_frame>Week 6</time_frame>
    <description>Measure of substitution for condition-specific tobacco products will be assessed using drug purchase tasks. Choices made during this task are not reinforced.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Average Daily ENDS Use</measure>
    <time_frame>Week 1 vs. Week 6</time_frame>
    <description>Number of ENDS puffs in the past day, collected via daily text survey, averaged over the past week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NNAL Exposure</measure>
    <time_frame>Week 1 vs. Week 6</time_frame>
    <description>A biomarker of combusted cigarette use collected from urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Proplyne Glycol Exposure</measure>
    <time_frame>Week 1 vs. Week 6</time_frame>
    <description>A biomarker of ENDS use collected from urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to Pay for ENDS</measure>
    <time_frame>Week 6</time_frame>
    <description>Willingness to pay for condition-specific tobacco products will be assessed using drug purchase tasks. Choices made during this task are not reinforced.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Electronic Nicotine Delivery System Flavors</condition>
  <arm_group>
    <arm_group_label>Menthol+Tobacco</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Menthol+Tobacco - where both menthol and tobacco flavored liquids for electronic nicotine delivery systems are available to choose from</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobacco</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobacco - where only tobacco flavored liquid is available for electronic nicotine delivery systems</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unflavored</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unflavored - where only unflavored liquid is available for electronic nicotine delivery systems</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tobacco product administration and assessment</intervention_name>
    <description>Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.</description>
    <arm_group_label>Menthol+Tobacco</arm_group_label>
    <arm_group_label>Tobacco</arm_group_label>
    <arm_group_label>Unflavored</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  between 21-55 years of age&#xD;
&#xD;
          -  identify as Black/African American (single or multi-race)&#xD;
&#xD;
          -  have used ≥5 cigarettes per day for ≥1 year&#xD;
&#xD;
          -  biochemically confirmed cigarette smoking status&#xD;
&#xD;
          -  regular cigarette brand is flavored to taste like menthol or mint&#xD;
&#xD;
          -  ENDS use in the past 30 days&#xD;
&#xD;
          -  report no intent to quit smoking in the next 6 months&#xD;
&#xD;
          -  previous quit attempt using evidence-based method&#xD;
&#xD;
          -  have a working mobile phone with a texting/data plan&#xD;
&#xD;
          -  are willing receive phone calls/text messages and complete internet-based/online&#xD;
             surveys related to the study.&#xD;
&#xD;
          -  read and write in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  are unwilling to use ENDS as part of the trial&#xD;
&#xD;
          -  report other tobacco use &gt;10 days in past 30 other than cigarettes&#xD;
&#xD;
          -  unstable or significant medical condition in the past 12 months&#xD;
&#xD;
          -  report &gt;15 days of marijuana use in the past 30 days&#xD;
&#xD;
          -  report any other illegal drug use in past 30 days&#xD;
&#xD;
          -  report intent to become pregnant or current pregnancy/breastfeeding&#xD;
&#xD;
          -  report any other condition that may affect participant safety or not allow them to&#xD;
             fully participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Barnes, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caroline O Cobb, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew J Barnes, PhD</last_name>
    <phone>804-827-4361</phone>
    <email>abarnes3@vcu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline O Cobb, PhD</last_name>
    <email>cobbco@vcu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electronic Nicotine Delivery System</keyword>
  <keyword>Electronic Cigarette</keyword>
  <keyword>Flavor</keyword>
  <keyword>Abuse Liability</keyword>
  <keyword>Toxicant Exposure</keyword>
  <keyword>Tobacco</keyword>
  <keyword>African American</keyword>
  <keyword>Menthol</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

